Dublin, May 14, 2021 (GLOBE NEWSWIRE) -- The "Immuno-Oncology Assays Market by Product & Service (Consumables, Instruments, Software), Technology (PCR, NGS, Immunoassay), Cancer Indications (Lung, Breast, Colorectal, Bladder, Melanoma), Application (Research, Diagnostics) - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
The global immuno-oncology assays market is projected to reach USD 7.9 billion by 2026 from USD 4.4 billion in 2021, at a CAGR of 12.5% during the forecast period.
Market growth is driven by factors such as the growing significance of companion diagnostics in drug development and rising incidence of cancer and growing adoption of targeted therapies. On the other hand, the requirement of high capital investments and low cost-benefit ratio and the unfavorable regulatory and reimbursement scenario are the major factors hampering the growth of this market.
The consumables segment accounted for the highest growth rate in the immuno-oncology assays market, by product & service, during the forecast period
The immuno-oncology assays market is segmented into consumables, instruments, and software & services based on product & service. In 2020, the consumables segment accounted for the highest growth rate in the immuno-oncology assays market. The requirement of consumables in large numbers as compared to instruments is the major factor contributing to the growth of this segment.
The research applications segment accounted for the highest CAGR
Based on application, the immuno-oncology assays market is segmented into research applications and clinical diagnostics. In 2020, the research applications segment accounted for the highest growth rate. This can be attributed to the rising prominence of biomarker-based drug development.
Asia Pacific: The fastest-growing region immuno-oncology assays market
The global immuno-oncology assays market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Growth in this region is expected to be centered on China and Japan. Factors such as the growing number of CROs in the region and the increasing awareness about the early detection of cancer are driving the growth of the immuno-oncology assays market in this region.
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights4.1 Immuno-Oncology Assays Market Overview4.2 Immuno-Oncology Assays Market Share, by Product & Service, 2021 Vs. 20264.3 Immuno-Oncology Assays Market Share, by Technology, 2021 Vs. 20264.4 Immuno-Oncology Assays Market Share, by Indication, 2021 Vs. 20264.5 Immuno-Oncology Assays Market Share, by Application, 2021 Vs. 20264.6 Immuno-Oncology Assays Market: Geographic Growth Opportunities
5 Market Overview5.1 Introduction5.2 Market Dynamics5.2.1 Drivers5.2.1.1 Rising Incidence of Cancer and Growing Adoption of Targeted Therapies5.2.1.2 Increased Demand for Personalized Medicine5.2.2 Restraints5.2.2.1 Requirement of High Capital Investments and Low Cost-Benefit Ratio5.2.2.2 Unfavorable Regulatory and Reimbursement Scenario5.2.2.3 High Cost of Immunotherapy5.2.3 Opportunities5.2.3.1 Emerging Markets Offer Lucrative Opportunities5.2.3.2 Growing Significance of Companion Diagnostics5.2.4 Challenges5.2.4.1 Low Awareness of Cancer Immunotherapy5.3 Impact of COVID-19 on the Immuno-Oncology Assays Market5.4 Pricing Analysis5.5 Patent Analysis5.6 Trade Analysis5.6.1 Trade Analysis for Diagnostic and Laboratory Reagents5.7 Value Chain Analysis5.8 Supply Chain Analysis5.9 Ecosystem Analysis of the Immuno-Oncology Assays Market5.10 Porter's Five Forces Analysis5.10.1 Threat of New Entrants5.10.2 Threat of Substitutes5.10.3 Bargaining Power of Buyers5.10.4 Bargaining Power of Suppliers5.10.5 Degree of Competition5.11 PESTLE Analysis5.12 Regulatory Landscape5.12.1 North America5.12.1.1 US5.12.1.2 Canada5.12.2 Europe5.12.3 Asia-Pacific5.12.3.1 Japan5.12.3.2 India5.12.4 Latin America5.12.4.1 Brazil5.12.4.2 Mexico5.12.5 Middle East5.12.6 Africa5.13 Technology Analysis5.14 Yc-Ycc Shift5.14.1 Yc-Ycc Shift for the Immuno-Oncology Assays Market
6 Immuno-Oncology Assays Market, by Product & Service6.1 Introduction6.2 Consumables6.2.1 Recurrent Purchase of Kits is a Major Factor Driving Market Growth6.3 Instruments6.3.1 Launch of Technologically Advanced Products to Support Market Growth6.4 Software & Services6.4.1 Increasing Need to Deliver Accurate and Timely Analysis of Diagnostic Tests to Support Market Growth
7 Immuno-Oncology Assays Market, by Technology7.1 Introduction7.2 Polymerase Chain Reaction7.2.1 Emergence of Advanced Pcr Technologies to Support Market Growth7.3 Immunoassay7.3.1 Immunoassays Have the Potential to Reduce Cancer Mortality Rate by Facilitating the Diagnosis of Cancer at an Early Stage7.4 Next-Generation Sequencing7.4.1 Ngs Segment to Grow at the Highest CAGR During the Forecast Period7.5 in Situ Hybridization7.5.1 High Demand for in Situ Hybridization in the Diagnosis of Small Tumors to Drive Market Growth7.6 Flow Cytometry7.6.1 Growing Incidence & Prevalence of Cancer to Support Market Growth
8 Immuno-Oncology Assays Market, by Indication8.1 Introduction8.2 Lung Cancer8.2.1 Increasing Research on Lung Cancer Biomarkers to Drive Market Growth8.3 Breast Cancer8.3.1 Increasing Government Funding for Breast Cancer Research to Drive Market Growth8.4 Colorectal Cancer8.4.1 Increasing Prevalence of Colorectal Cancer to Propel Market Growth8.5 Bladder Cancer8.5.1 Bladder Cancer Segment to Witness Slower Growth Owing to the Limited Adoption of Immuno-Oncology Assays8.6 Melanoma8.6.1 Growing Incidence of Melanoma to Drive the Demand for Immuno-Oncology Assays8.7 Other Cancers
9 Immuno-Oncology Assays Market, by Application9.1 Introduction9.2 Research Applications9.2.1 Rising Prominence of Biomarker-Based Drug Development to Drive the Research Applications Market9.3 Clinical Diagnostics9.3.1 Benefits of Immuno-Oncology Assays are Driving Their Adoption in Clinical Diagnostics
10 Immuno-Oncology Assays Market, by Region10.1 Introduction10.2 North America10.3 Europe10.4 Asia-Pacific10.5 Latin America10.6 Middle East & Africa
11 Competitive Landscape11.1 Overview11.2 Key Player Strategies11.3 Revenue Share Analysis of Top Market Players11.4 Market Share Analysis11.5 Company Evaluation Quadrant11.5.1 List of Evaluated Vendors11.5.2 Stars11.5.3 Emerging Leaders11.5.4 Pervasive Players11.5.5 Participants11.6 Competitive Leadership Mapping for Startups/Smes (2020)11.6.1 Progressive Companies11.6.2 Starting Blocks11.6.3 Responsive Companies11.6.4 Dynamic Companies11.7 Product and Geographical Footprint Analysis of Top Players11.8 Competitive Scenario11.8.1 Market Evaluation Framework, 2018-202011.8.2 Product Launches & Regulatory Approvals11.8.3 Deals11.8.4 Other Developments
12 Company Profiles12.1 Key Players12.1.1 Thermo Fisher Scientific, Inc.12.1.2 F. Hoffmann-La Roche Ltd.12.1.3 Illumina, Inc.12.1.4 Merck Millipore12.1.5 Agilent Technologies, Inc.12.1.6 Abbott Laboratories, Inc.12.1.7 Sartorius Ag12.1.8 Nanostring Technologies, Inc.12.1.9 Htg Molecular Diagnostics, Inc.12.1.10 Perkinelmer, Inc.12.1.11 Qiagen N.V.12.2 Other Players12.2.1 Biomerieux Sa12.2.2 Myriad Genetics, Inc.12.2.3 Guardant Health, Inc.12.2.4 Bio-Rad Laboratories, Inc.12.2.5 Charles River Laboratories, Inc.12.2.6 Seegene Inc.12.2.7 Meso Scale Diagnostics, LLC.12.2.8 Olink12.2.9 Asuragen, Inc.12.2.10 Invivoscribe, Inc.12.2.11 Creative Biolabs12.2.12 Reachbio LLC12.2.13 Nmi Technologietransfer GmbH
13 Appendix13.1 Insights from Industry Experts13.2 Discussion Guide13.3 Knowledge Store: The Subscription Portal13.4 Available Customizations
For more information about this report visit